Jack Nathan Medical (JNH) AI Stock Analysis

• Market Cap: C$413.49K
• Dividend Yield: N/A
• Average Volume (3M): 29.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.26
• Revenue Growth: 22.44%
• EPS Growth: -3.91%
• Country: CA
• Employees: 24
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 41,349,160
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 29,119
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Jack Nathan Medical faces substantial financial challenges, including negative profitability and high leverage, which severely impact its stock score. Technical indicators and valuation metrics further reinforce the cautious outlook, with weak price momentum and unattractive valuation measures.

Jack Nathan Medical Business Overview & Revenue Model

Company Description

Jack Nathan Medical (JNH) is a provider of primary care medical clinics and services, primarily operating within retail environments. The company focuses on delivering accessible healthcare solutions, co-locating its clinics within major retail partners to enhance convenience for patients. Jack Nathan Medical aims to improve healthcare accessibility and affordability by integrating medical services into everyday retail settings.

How the Company Makes Money

Jack Nathan Medical makes money through several key revenue streams. Primarily, the company generates revenue by offering medical services to patients in its clinics, which are often situated in high-traffic retail locations. These services include general practitioner consultations, preventative care, and minor medical procedures. Additionally, the company may receive funding from partnerships with retail chains, enabling them to establish clinics inside their stores. These partnerships help reduce overhead costs and provide a steady flow of potential patients due to the retail foot traffic. Furthermore, Jack Nathan Medical may leverage strategic alliances and collaborations with healthcare providers and insurers, enhancing service offerings and expanding patient reach, thus contributing to its revenue.

Jack Nathan Medical Financial Statement Overview

Summary

Jack Nathan Medical demonstrates revenue growth but faces significant challenges in profitability and liquidity. Persistent losses, negative equity, and substantial debt levels indicate high financial risk, while negative cash flows highlight potential sustainability issues.

Income Statement

The company has shown revenue growth, with a significant increase from 2023 to 2024. However, profitability remains a major concern as both gross and net profit margins are negative, indicating persistent losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet reveals a highly leveraged position with negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is also negative, highlighting a concerning level of liabilities compared to assets.

Cash Flow

The company is experiencing negative operating and free cash flows, which is a critical issue for sustainability. Although financing cash flow is positive, it primarily stems from high financing activities, which may not be sustainable in the long run. Operating cash flow to net income ratio is negative, suggesting cash flow challenges.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Dec 2018
Income Statement
Total Revenue	21.33M	19.14M	15.49M	9.64M	3.85M	0.00
Gross Profit	17.77M	14.48M	11.82M	6.92M	3.74M	0.00
EBITDA	-5.98M	-4.96M	-5.51M	-7.54M	-10.11M	778.25K
Net Income	-8.29M	-6.64M	-7.08M	-7.81M	-9.90M	-18.09K
Balance Sheet
Total Assets	6.66M	11.19M	6.45M	10.65M	406.78K	84.20K
Cash, Cash Equivalents and Short-Term Investments	365.22K	3.07M	1.46M	7.69M	406.78K	84.20K
Total Debt	13.87M	12.39M	4.55M	713.02K	713.02K	0.00
Total Liabilities	18.70M	17.13M	8.32M	2.13M	17.18K	8.00K
Stockholders Equity	-12.04M	-5.95M	-1.87M	8.53M	389.59K	76.20K
Cash Flow
Free Cash Flow	-5.13M	-10.20M	-4.59M	-1.31M	-566.27K	-33.69K
Operating Cash Flow	-6.94M	-6.11M	-2.00M	-809.16K	-66.53K	-33.69K
Investing Cash Flow	-2.05M	-4.09M	-2.69M	-252.89K	-252.89K	0.00
Financing Cash Flow	4.01M	11.91M	5.28M	8.68M	389.11K	50.00K

Jack Nathan Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:JNH, the sentiment is Negative. The current price of 0.01 is equal to the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.62 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:JNH.

Jack Nathan Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WELL	67 Neutral	C$1.08B	30.45	-3.53%	―	17.19%	-191.01%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%
PTX	38 Underperform	C$11.88M	―	-42.50%	―	―	31.86%
JNH	34 Underperform	C$413.49K	―	111.59%	―	22.44%	-3.91%

Jack Nathan Medical Corporate Events

Jack Nathan Health Reports Q3 Fiscal 2025 Results

Jack Nathan Health reported a 16% year-to-date revenue growth in its Q3 fiscal 2025 results, driven primarily by its expanding operations in Mexico. The company has completed the sale of its Canadian operations and is focusing on growing its Mexican clinics and exploring opportunities in the MedSpa sector.

Jack Nathan Health Sells Canadian Business for Growth

Jack Nathan Health has completed the sale of its Canadian business to WELL Health Technologies for Cdn$5 million, eliminating over Cdn$15 million in debt and streamlining its capital structure. The company will focus on its profitable Mexican operations, including clinics in Walmart locations, while securing future growth through a cash infusion from the asset sale.